相关人员
Oliver advises on M&A transactions, primarily in the healthcare sector. His portfolio in the healthcare sector includes the structuring, negotiation and implementation of complex transactions for national and international investors, in particular for private equity investors upon their entry to the market.
Since 2007 | Partner, Taylor Wessing |
2002 – 2007 | Associate, international law firm, Düsseldorf |
2005 – 2006 | Secondee, Slaughter and May, Hong Kong |
2002 | Admitted as a lawyer, Düsseldorf |
2001 | Second state examination, Hamburg |
2001 – 2003 | Doctoral degree, Universität in Mainz |
1998 – 1999 | Studies, Hochschule für Sprache und Kultur, Peking |
1998 | First state examination, Regensburg |
1993 – 1998 | Degree in law, Universität Regensburg |
Post-Merger Integration und Corporate Governance bei chinesischen Outbound-Investitionen in Deutschland, in: Chinesische Outbound-Investitionen in Deutschland, Hrsg. Von Prof. Yuanshi Bu, 2014“ Kulturelle Besonderheiten bei Verhandlungen und Vertragsmanagement, Unternehmeredition M & A China / Deutschland 2013 |
Gesellschaftsrechtliche Vereinigung (VGR) |
English |
最新新闻和观点
Chambers Europe 2022 recommends 28 Taylor Wessing lawyers from 21 Practice Areas whilst Data Protection is listed for the first time
作者
Top Level Change at Taylor Wessing Germany: Olaf Kranz elected as new Managing Partner
作者
New Competition Rules for R&D Cooperation Agreements
作者 Stephan Manuel Nagel, LL.M. (EUI) 以及 Dr. Nora E. Wessendorf, LL.M. (Washington)
Does a clinical trial render the pharmaceutical formulation used therein public?